Treating Depression Where It Starts
A revolutionary depression treatment that has changed the field of mental healthcare, Deep TMS™ has been FDA-cleared to safely and effectively treat Major Depressive Disorder (MDD) through BrainsWay’s patented H-coil technology.
Deep TMS treatment for depression works by utilizing a magnetic field that manages to directly reach wider and deeper brain regions, regulating the neural activity of brain structures related to major depressive disorder – specifically the dorsolateral prefrontal cortex (DLPFC).
Repeated peer-reviewed studies have found Deep TMS to be a highly effective treatment that can facilitate a profound improvement in patients’ mental health, alleviating symptoms of depression and contributing to a significantly greater quality of life.
As a noninvasive procedure, Deep TMS is a well-tolerated treatment that does not cause any adverse or long-lasting side effects. It does not require a significant recovery period, and the 20-min treatment can easily be integrated into each patient’s day-to-day schedule. An accelerated treatment option, called SWIFT™ Deep TMS, is also FDA-cleared, shortening the acute treatment phase from 4 weeks to 6 days and individual treatment sessions to 10-min.
Advanced treatment for depression, without medication. BrainsWay Deep TMS is a noninvasive, outpatient treatment that takes as little as 20 minutes per day. During each session, a comfortable cushioned helmet is placed over your head while magnetic pulses deliver the therapy to the treatment location which regulates mood in your brain.
You may feel a tapping, tingling, or warming sensation during treatment which will subside after the session completes. You will be awake and alert during the treatment and may resume regular activities immediately afterward.
BrainsWay Deep TMS is a safe, proven alternative for treating major depression.
Try TMS – A Proven Alternative Treatment for Depression
The 9-question Patient Health Questionnaire (PHQ-9) is a diagnostic tool introduced in 2001 to screen adult patients in a primary care setting for the presence and severity of depression. It rates depression based on the self-administered Patient Health Questionnaire (PHQ). The PHQ is part of Pfizer’s larger suite of trademarked products, called the Primary Care Evaluation of Mental Disorders (PRIME-MD). The PHQ-9 takes less than 3 minutes to complete and simply scores each of the 9 DSM-IV criteria for depression based on the mood module from the original PRIME-MD. Primary care providers frequently use the PHQ-9 to screen for depression in patients.
